A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
6 Jun 2016: Trial registered, NCT02790515
14 Jul 2016: Trial started, NCT02790515
The trials
NCT02790515: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
State
Under way
Phase
Phase 2
People
170 taking part
Started
14 Jul 2016
Primary completion
1 Jul 2025
Arms
Treatment
Results
None posted
6 Jun 2016: Trial registered
14 Jul 2016: Trial started
How the status changed
19 Nov 2026: First set: Phase 2 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.